Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

GlobeNewswire August 9, 2021

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress

GlobeNewswire August 5, 2021

Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

GlobeNewswire August 2, 2021

Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer

GlobeNewswire July 15, 2021

Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021

GlobeNewswire July 8, 2021

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

GlobeNewswire June 15, 2021

Autolus Therapeutics Announces an Additional Nature Publication for AUTO1

GlobeNewswire May 25, 2021

Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021

GlobeNewswire May 21, 2021

Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress

GlobeNewswire May 12, 2021

Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress

GlobeNewswire May 6, 2021

Autolus Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call on May 6

GlobeNewswire April 26, 2021

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

GlobeNewswire April 20, 2021

Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman

GlobeNewswire April 19, 2021

Autolus Therapeutics to Participate in Investor Conferences Through April

GlobeNewswire April 1, 2021

Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL

GlobeNewswire April 1, 2021

Autolus Therapeutics Announces Updated Manufacturing Facility Strategy Leveraging its UK Operations

GlobeNewswire March 29, 2021

Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

GlobeNewswire March 4, 2021

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire February 24, 2021

Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs

GlobeNewswire February 12, 2021

Autolus Announces Pricing of Public Offering

GlobeNewswire February 9, 2021